Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1/L1 Inhibitor”

131 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 131 results

Early research (Phase 1)Ended earlyNCT02936102
What this trial is testing

FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Who this might be right for
Advanced Solid TumorsTriple Negative Breast CancerChordoma and Alveolar Soft Part Sarcoma
Novartis Pharmaceuticals 154
Large-scale testing (Phase 3)Active Not RecruitingNCT04246177
What this trial is testing

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Who this might be right for
Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC 480
Testing effectiveness (Phase 2)Active Not RecruitingNCT06558799
What this trial is testing

LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
NovoCure GmbH 69
Testing effectiveness (Phase 2)Active Not RecruitingNCT03600701
What this trial is testing

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaRefractory Lung Non-Small Cell Carcinoma+1 more
National Cancer Institute (NCI) 51
Testing effectiveness (Phase 2)Active Not RecruitingNCT05604560
What this trial is testing

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Who this might be right for
Pancreatic Cancer
Lei Zheng 25
Large-scale testing (Phase 3)Looking for participantsNCT06103864
What this trial is testing

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 625
Testing effectiveness (Phase 2)Active Not RecruitingNCT03228667
What this trial is testing

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Who this might be right for
Non-Small Cell Lung CancerSmall Cell Lung CancerUrothelial Carcinoma+10 more
ImmunityBio, Inc. 40
Not applicableLooking for participantsNCT06693440
What this trial is testing

The Immune Assessment of PD-1 Antibody Therapy in Tumor

Who this might be right for
Efficacy, TeamAdverse Event
Quanli Gao 3,000
Not applicableLooking for participantsNCT05717738
What this trial is testing

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma Non-resectable
Tongji Hospital 300
Testing effectiveness (Phase 2)Study completedNCT03797326
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Who this might be right for
Advanced Solid TumorsTriple Negative Breast CancerOvarian Cancer+5 more
Merck Sharp & Dohme LLC 611
Not applicableStudy completedNCT03387540
What this trial is testing

Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions

Who this might be right for
MyocarditisCardiac Complication
Groupe Hospitalier Pitie-Salpetriere 104
Early research (Phase 1)Looking for participantsNCT05098210
What this trial is testing

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Cutaneous Melanoma+22 more
Fred Hutchinson Cancer Center 25
Testing effectiveness (Phase 2)Study completedNCT03989362
What this trial is testing

Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer

Who this might be right for
Cancer
Jounce Therapeutics, Inc. 61
Not applicableActive Not RecruitingNCT05364086
What this trial is testing

An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study

Who this might be right for
Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm
University of Rochester NCORP Research Base 2,100
Large-scale testing (Phase 3)Study completedNCT04799249
What this trial is testing

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

Who this might be right for
TNBC - Triple-Negative Breast CancerBreast Cancer
G1 Therapeutics, Inc. 194
Early research (Phase 1)Study completedNCT03340766
What this trial is testing

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Who this might be right for
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Amgen 31
Testing effectiveness (Phase 2)Looking for participantsNCT05361174
What this trial is testing

Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Who this might be right for
Unresectable MelanomaMetastatic MelanomaStage III Non-small Cell Lung Cancer+1 more
Iovance Biotherapeutics, Inc. 53
Early research (Phase 1)Active Not RecruitingNCT04387084
What this trial is testing

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Who this might be right for
Advanced Malignant Skin NeoplasmMetastatic Malignant Skin Neoplasm
University of Southern California 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT03607890
What this trial is testing

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Who this might be right for
Refractory MSI - H Solid Tumors Prior of PD-(L) 1 TherapyMSI-H Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 38
Testing effectiveness (Phase 2)Ended earlyNCT03606174
What this trial is testing

Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Urothelial CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma Ureter+2 more
Mirati Therapeutics Inc. 260
Load More Results